The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID.

英国间质性肺病长-COVID19研究（UKILD-Long COVID）：了解长-COVID中间质性肺病的负担。

• 批准号: MR/W006111/1
• 负责人: Gisli Jenkins
• 金额: $ 256.75万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FW006111%2F1
• 关键词: UK; Interstitial; Lung; Disease; Long

Many recovering COVID-19 patients suffer from long term symptoms, including breathlessness and fatigue, so-called "Long COVID". Recent data suggest that between 10-20% of patients who do not go into hospital and 40-60% of people discharged from hospital suffer from symptoms of Long COVID.The COVID-19 pandemic has led to a huge number of infected people throughout the world with a substantial number requiring hospital-based care. In the UK alone, there have been over 3.5 million people known to be infected of whom more than 350,000 people were hospitalised, with over 25,000 admitted to intensive care units. The commonest reason for hospital admission is COVID pneumonitis. If this progresses to Adult Respiratory Distress Syndrome, patients may be admitted to Intensive Care Wards , where they could be placed on a ventilator to support them through their illness.Recent analysis indicates that inflammatory and scarring lung diseases (known as Interstitial Lung diseases - ILD) are a major complication of COVID pneumonitis and occur in approximately 20% of patients discharged from hospital. The figure is thought to be even higher in patients discharged from Intensive Care Units. Although the exact number of people affected is not yet known, there is an urgent need to identify and prevent the development of this potential severe complication, which can lead to irreversible scarring.Therefore, to improve outcomes for survivors of COVID pneumonitis we will undertake a clinical study to identify how many people develop ILD following COVID-19, what types of ILD they develop (is it predominantly inflammation or scarring) and why they do so. We will ask patients with possible ILD if they would be willing to have a CT scan to confirm whether they have this disease. If they do, we will invite these patients to undergo investigations using a range of new technologies. These will include Xenon Magnetic Resonance Imaging to get more detailed analysis of the changes in the function of different parts of the lung and Bronchoalveolar Lavage to analyse cells from the lung to understand whether the severity of COVID-19 or its treatments make a difference to the development of ILDs. We will identify whether COVID-19 leads primarily to either inflammatory or scarring disease and whether this disease gets better or worse in the year after they are discharged from hospital. Finally, we will try to understand why some patients get severe lung disease following COVID-19, and others don't, and identify blood markers and genes that increase the risk of developing long-term scarring, so that we can determine how to treat patients and prevent the development of substantial scarring.Understanding these questions will help us to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19 infection.

许多康复中的COVID-19患者患有长期症状，包括呼吸困难和疲劳，即所谓的“长期COVID”。最近的数据显示，10-20%的未住院患者和40-60%的出院患者患有长期COVID的症状。COVID-19大流行导致全球大量感染者，其中大量患者需要住院治疗。仅在英国，已知有超过350万人感染，其中超过35万人住院，超过25，000人入住重症监护室。入院的最常见原因是COVID肺炎。如果进展为成人呼吸窘迫综合征，患者可能会被送入重症监护病房，在那里他们可以被放置在呼吸机上以支持他们的疾病。最近的分析表明，炎症和瘢痕性肺部疾病（称为间质性肺疾病- ILD）是COVID肺炎的主要并发症，大约20%的患者出院时会发生。据信，从重症监护室出院的患者中，这一数字甚至更高。虽然受影响的确切人数尚不清楚，但迫切需要识别和预防这种可能导致不可逆疤痕的潜在严重并发症的发展。因此，为了改善COVID肺炎幸存者的结局，我们将开展一项临床研究，以确定有多少人在COVID-19后发生ILD，他们发展出什么类型的ILD（主要是炎症还是瘢痕）以及为什么会这样。我们将询问可能患有ILD的患者是否愿意接受CT扫描以确认他们是否患有这种疾病。如果他们这样做，我们将邀请这些患者接受使用一系列新技术的调查。这些将包括氙磁共振成像，以更详细地分析肺不同部位的功能变化，以及支气管肺泡灌洗，以分析肺细胞，以了解COVID-19的严重程度或其治疗是否会影响ILD的发展。我们将确定COVID-19是否主要导致炎症性或瘢痕性疾病，以及这种疾病在他们出院后的一年内是好转还是恶化。最后，我们将试图了解为什么有些患者在COVID-19后会患上严重的肺部疾病，而其他人则不会，并确定增加长期疤痕风险的血液标志物和基因，这样我们就可以确定如何治疗病人和防止严重疤痕的发展。理解这些问题将有助于我们制定治疗策略，以防止严重疤痕和残疾的发展在COVID-19感染后。

项目成果

Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.

• DOI: 10.1016/j.immuni.2022.01.017
• 发表时间: 2022-03-08
• 期刊: Immunity
• 影响因子: 32.4
• 作者: Vijayakumar B;Boustani K;Ogger PP;Papadaki A;Tonkin J;Orton CM;Ghai P;Suveizdyte K;Hewitt RJ;Desai SR;Devaraj A;Snelgrove RJ;Molyneaux PL;Garner JL;Peters JE;Shah PL;Lloyd CM;Harker JA
• 通讯作者: Harker JA

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.

• DOI: 10.1016/s2213-2600(23)00124-8
• 发表时间: 2023-08
• 期刊: The Lancet. Respiratory medicine

Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID-19 Study.

• DOI: 10.1164/rccm.202203-0564oc
• 发表时间: 2023-03-15
• 期刊: American journal of respiratory and critical care medicine
• 影响因子: 24.7

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.

• DOI: 10.1016/j.ebiom.2022.104402
• 发表时间: 2023-01
• 期刊: EBIOMEDICINE
• 影响因子: 11.1
• 作者: Liew, Felicity;Talwar, Shubha;Cross, Andy;Willett, Brian J.;Scott, Sam;Logan, Nicola;Siggins, Matthew K.;Swieboda, Dawid;Sidhu, Jasmin K.;Efstathiou, Claudia;Moore, Shona C.;Davis, Chris;Mohamed, Noura;Nunag, Jose;King, Clara;Thompson, A. A. Roger;Rowland-Jones, Sarah L.;Docherty, Annemarie B.;Chalmers, James D.;Ho, Ling-Pei;Horsley, Alexander;Raman, Betty;Poinasamy, Krisnah;Marks, Michael;Kon, Onn Min;Howard, Luke;Wootton, Daniel G.;Dunachie, Susanna;Quint, Jennifer K.;Evans, Rachael A.;V. Wain, Louise;Fontanella, Sara;Silva, Thushan I. de;Ho, Antonia;Harrison, Ewen;Baillie, J. Kenneth;Semple, Malcolm G.;Brightling, Christopher;Thwaites, Ryan S.;Turtle, Lance;Openshaw, Peter J. M.
• 通讯作者: Openshaw, Peter J. M.

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.

• DOI: 10.1016/j.eclinm.2023.101896
• 发表时间: 2023-03
• 期刊: ECLINICALMEDICINE
• 影响因子: 15.1
• 作者: McAuley, Hamish J. C.;Evans, Rachael A.;Bolton, Charlotte E.;Brightling, Christopher E.;Chalmers, James D.;Docherty, Annemarie B.;Elneima, Omer;Greenhaff, Paul L.;Gupta, Ayushman;Harris, Victoria C.;Harrison, Ewen M.;Ho, Ling-Pei;Horsley, Alex;Houchen-Wolloff, Linzy;Jolley, Caroline J.;Leavy, Olivia C.;Lone, Nazir I.;Man, William D. C.;Marks, Michael;Parekh, Dhruv;Poinasamy, Krisnah;Quint, Jennifer K.;Raman, Betty;Richardson, Matthew;Saunders, Ruth M.;Sereno, Marco;Shikotra, Aarti;Singapuri, Amisha;Singh, Sally J.;Steiner, Michael;Tan, Ai Lyn;Wain, Louise, V;Welch, Carly;Whitney, Julie;Witham, Miles D.;Lord, Janet;Greening, Neil J.;HOSP-COVID Study Collaborat Grp
• 通讯作者: HOSP-COVID Study Collaborat Grp